On the stock market since 1997, it operates in the world of health and science. It has 808 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 56% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 28% a year on average.
Sales run at $257.3M a year. A small number, but proof the product has real buyers.
There is $156.6M in the vault; even if every debt were paid off, $53.5M would remain.
A loss of $18.4M against $257.3M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, HSKA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: HSKA is a high-risk stock — not yet profitable, and its future rides on its product catching on.